Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790490 · ClinicalTrials.gov registry record · Phase 2
Glutamatergic Modulation of Cocaine-related Deficits
A Phase 2 study of Cocaine Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01790490 is a Phase 2 study of Cocaine Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01790490, a Phase 2 study of Cocaine Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human subjects have been unsuccessful to date. The purpose of this investigation is to examine the effects of the NMDAr antagonist ketamine, recently found to have potent therapeutic effects in humans, on cue-induced craving and impaired motivation for quitting cocaine in cocaine dependent participants, 24-hours post-infusion.
Conditions Studied
Interventions
- DRUG Ketamine 0.41 mg/kg
- DRUG Ketamine 0.71 mg/kg
- DRUG Lorazepam 2 mg
Study Locations (1)
New York
- NYSPI - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790490
The ClinicalTrials.gov registry entry for NCT01790490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (97% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Ketamine 0.41 mg/kg is the first listed.
NCT01790490 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01790490 about?
NCT01790490 is a clinical study titled "Glutamatergic Modulation of Cocaine-related Deficits". Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human su...
What is the current status of trial NCT01790490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-02. Estimated completion is 2012-03.
What conditions does trial NCT01790490 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT01790490?
The interventions under investigation include: Ketamine 0.41 mg/kg (DRUG), Ketamine 0.71 mg/kg (DRUG), Lorazepam 2 mg (DRUG).
Who is sponsoring clinical trial NCT01790490?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01790490 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
-
Clinical Trial of Topiramate for Cocaine Addiction
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.